Jason Holman
Healthcare, biotech, event-driven, Defense

MacroGenics: A Balanced Small Cap Bio With A Great Entry Level Opportunity

Investing in the speculative biotech sector is an extremely risky endeavor that can prove to be a great boon for some but lead to substantive losses for others. This particular investing landscape is populated with trial data releases, FDA decisions, FDA designation and manipulation while often not having extensive revenue data to validate market capitalizations in a concrete manner. In the absence of these typical indicators of a company's current value vs. future value it becomes an investor's responsibility to track other potential indications to establish value and worth amongst the hundreds of opportunities in the sector. A method that has assisted in navigating the plethora of bio spec opportunities is categorically dissecting these different indicators that assist in substantially...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details